Boehringer Ingelheim to advance potential new treatment for GA following Phase 1 results
September 10th 2024BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Read More
Research team works to help prevent vision loss linked with space travel
August 27th 2024Researchers at the Medical College of Georgia at Augusta University are teaming up with Polaris Dawn to gain a better understanding of how eye changes many astronauts experience during spaceflight could ultimately leave them with multiple symptoms once they return to Earth.
Read More
ASRS releases public service announcement that shines spotlight on retina specialist care
August 16th 2024In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.
Read More
Eye surgery showcase goes to Australian Parliament House
August 16th 2024The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.
Read More
University of Washington researchers to study the genetic causes of inherited retinal diseases
August 13th 2024Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.
Read More
Study examines use of AI for early detection of pediatric eye diseases using mobile photos
August 9th 2024Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.
Read More
Annexon provides update on ARCHER II global registrational program in geographic atrophy
August 5th 2024According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.
Read More